Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - UroGen Pharma Ltd. | urgn-ex321_12.htm |
| EX-31.2 - EX-31.2 - UroGen Pharma Ltd. | urgn-ex312_10.htm |
| EX-31.1 - EX-31.1 - UroGen Pharma Ltd. | urgn-ex311_7.htm |
| EX-23.2 - EX-23.2 - UroGen Pharma Ltd. | urgn-ex232_262.htm |
| EX-21.1 - EX-21.1 - UroGen Pharma Ltd. | urgn-ex211_13.htm |
| 10-K - 10-K - UroGen Pharma Ltd. | urgn-10k_20201231.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-235642) and Form S-8 (Nos. 333-243750, 333-232034, 333-227812, 333-222955, 333-221212 and 333-218992) of UroGen Pharma Ltd. of our report dated March 18, 2021 relating to the financial statements, which appears in this Form 10-K.
/s/PricewaterhouseCoopers LLP
Florham Park, New Jersey
March 18, 2021
|
Kesselman & Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel, |
|
P.O Box 50005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il |